BRIDGING CHASMS IN BLADDER CANCER CARE
Activity Overview
This educational session will comprehensively evaluate the current state of the bladder cancer management paradigm and investigate the emergence of new data across the totality of the disease continuum, with a particular emphasis on evidence-based treatment sequencing and the role of antibody-drug conjugates (ADCs) in subsequent lines of therapy for advanced disease. To conclude the session, activity attendees will get to apply the therapeutic principles they’ve learned to real-world clinical scenarios which will focus on patient-centric treatment selection and sequencing, as well as recognition, mitigation, and management of treatment-related adverse events.
Pre-registration is encouraged for this activity, but not required. As a pre-registrant, we will reserve seating for you until 15 minutes prior to the start of the activity. After that time, we will begin accepting walk-in registrations.
Thursday, February 16, 2023 7:00 PM - 9:00 PM PT
Marriott Marquis | Golden Gate Ballroom A | San Francisco, CA
Earn CE/CME.
By entering your mobile phone number you agree that CE Concepts can send you periodic text messages about CME/CE activities. This free service is FCC CAN-SPAM compliant. You may update message preferences or unsubscribe at any time. Check your wireless provider for any message and data rates that may apply.
Expert Faculty
Petros Grivas, MD, PhD
(Activity Chair)
Professor, Division of Medical Oncology
University of Washington School of Medicine
Clinical Director, Genitourinary Cancers Program
UW Medicine
Professor, Clinical Research Division
Fred Hutch
Seattle, WA
Sam S. Chang MD, MBA
Patricia and Rodes Hart Endowed Chair of Urologic Surgery
Professor of Urology and Oncology
Chief Surgical Officer, Vanderbilt Ingram Cancer Center
Nashville, TN
Scott T. Tagawa, MD, MS, FACP
Professor of Medicine and Urology
Weill Cornell Medicine
Attending Physician
NewYork-Presbyterian
Weill Cornell Medical Center
New York, NY
Learning Objectives
- Examine recent evolutions in the bladder cancer management calculus across the totality of the disease
- Appraise the expanding clinical trial evidentiary base for ADCs in metastatic disease, including regulatory updates, recent readouts, and current expert consensus guideline recommendations.
- Discuss the unique clinical potential of ADCs in mUC, particularly in subsequent lines of therapy, and evaluate ongoing and prospective ADC clinical trials, both as monotherapy and as part of combinatorial regimens with ICIs.
- Using real-world cases that incorporate the patient voice, design evidence-supported bladder cancer treatment plans, both in first-line and post-progression, by integrating guideline recommendations with patient-specific and disease-specific factors (i.e., performance status, renal function, PD-L1 expression, FGFR mutation, cytopathology, urinary markers, etc.).
- Recognize, mitigate, and manage treatment-related adverse events in patients with advanced bladder cancer.
Program
5 min Welcome and Introductions/Pre-test
20 min A Paradigm in Flux: Diving Deep into Evolving Standards of Care Across the Bladder Cancer Disease Continuum
20 min ADCs in mUC: The Expanding Evidentiary Base, Evolving Consensus Guidelines, and Patient-Centric Considerations
30 min Case-driven Catalysts: An Expert Roundtable Discussion on Evidence-based Treatment Sequencing in Bladder Cancer
15 min Conversations with the Experts/Audience Q&A/Post-test
Accreditation
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of a CE request form, statements of credit will be issued within 30 days
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
Not an official event of the 2023 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.
Presented by Creative Educational Concepts, LLC (CEC Oncology) in collaboration with the Bladder Cancer Advocacy Network (BCAN).
There is no fee to participate in this activity.
Supported through an independent educational grant from Gilead.